Live Breaking News & Updates on Antibody radiation conjugates

Stay informed with the latest breaking news from Antibody radiation conjugates on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Antibody radiation conjugates and stay connected to the pulse of your community

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Glasgow , Glasgow-city , Scotland , Bristol-meyers , Novo-nordisk , Group-fedwatch , Rhythm-pharmaceuticals , Phathom-pharmaceuticals , Exchange-commission , Astrazeneca , Federal-reserve

Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML

Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Glasgow , Glasgow-city , Scotland , Hannah-choe , European-bone-marrow-transplant-society-meeting , Professor-of-medicine-at-ohio-state-university , Prnewswire-actinium-pharmaceuticals-inc , Overall-survival , Antibody-radiation-conjugates , Complete-remission , Assistant-professor

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Glasgow , Glasgow-city , Scotland , Avinash-desai , Actimaba-national-cancer-institute , Exchange-commission , European-bone-marrow-transplant-society , Actinium-pharmaceuticals-inc , Actinium-pharmaceuticals , Antibody-radiation-conjugates , Complete-remission

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved...

United-states , American , Avinash-desai , Sandesh-seth , Exchange-commission , Actimaba-national-cancer-institute , Actinium-pharmaceuticals-inc , Prnewswire-actinium-pharmaceuticals-inc , International-blood-marrow-transplant-research , American-society-for-transplantation , Antibody-radiation-conjugates , Texas-southwestern-medical-center

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target Raised to $27.00

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) had its price target raised by Cantor Fitzgerald from $26.00 to $27.00 in a report published on Tuesday, The Fly reports. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2023 earnings at ($1.69) EPS. A number of other analysts have also recently issued reports on the company. William Blair […]

New-york , United-states , William-blair , Corton-capital-inc , Actinium-pharmaceuticals-company-profile , News-ratings-for-actinium-pharmaceuticals-daily , Actinium-pharmaceuticals-inc , Actinium-pharmaceuticals , Delphia-united-states-inc , Actinium-pharmaceuticals-stock , Man-group , Hedge-funds-weigh-in-on-actinium-pharmaceuticals

Analysts Set Expectations for Actinium Pharmaceuticals, Inc.'s FY2025 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Rating) – HC Wainwright dropped their FY2025 EPS estimates for shares of Actinium Pharmaceuticals in a report released on Monday, April 3rd. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn $1.34 per share for the year, down from their previous forecast of $1.49. HC […]

New-york , United-states , Blackrock , William-blair , Hedge-funds-weigh-in-on-actinium-pharmaceuticals , News-ratings-for-actinium-pharmaceuticals-daily , Blackrock-inc , Actinium-pharmaceuticals , Virtu-financial , Actinium-pharmaceuticals-inc , Renaissance-technologies , Blair-william-co

Cantor Fitzgerald Raises Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target to $27.00

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) had its target price hoisted by Cantor Fitzgerald from $26.00 to $27.00 in a research report report published on Tuesday, The Fly reports. Several other equities research analysts have also recently commented on the company. HC Wainwright reissued a buy rating and issued a $53.00 price target on shares […]

New-york , United-states , William-blair , Cantor-fitzgerald , Man-group , Actinium-pharmaceuticals-inc , Institutional-investors-weigh-in-on-actinium-pharmaceuticals , Actinium-pharmaceuticals-trading , Capital-management , Corton-capital-inc , Actinium-pharmaceuticals , News-ratings-for-actinium-pharmaceuticals-daily

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Issues Earnings Results

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) released its quarterly earnings data on Monday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01), MarketWatch Earnings reports. Actinium Pharmaceuticals had a negative return on equity of 41.64% and a negative net margin of 2,885.09%. Actinium Pharmaceuticals […]

New-york , United-states , William-blair , News-ratings-for-actinium-pharmaceuticals-daily , Earnings-history-for-actinium-pharmaceuticals , Actinium-pharmaceuticals-stock-performance , Cantor-fitzgerald , Millennium-management , Actinium-pharmaceuticals-inc , Man-group , Cubist-systematic-strategies , Marshall-wace

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Downgraded by StockNews.com

StockNews.com downgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) from a hold rating to a sell rating in a report released on Friday morning. A number of other analysts have also weighed in on the stock. William Blair lowered shares of Actinium Pharmaceuticals from an outperform rating to a market perform rating in a […]

New-york , United-states , William-blair , Actinium-pharmaceuticals-company-profile , Actinium-pharmaceuticals-stock-performance , Millennium-management , Virtu-financial , News-ratings-for-actinium-pharmaceuticals-daily , Actinium-pharmaceuticals , Global-investors , Man-group , Institutional-trading-of-actinium-pharmaceuticals

Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for...

New-york , United-states , Memorial-sloan-kettering-cancer-center , Hans-vitzthum , Lifesci-advisors , Lotte-new-york-palace-hotel , Exchange-commission , Astellas-pharma-inc , Actinium-pharmaceuticals-inc , Epicentrx-inc , Prnewswire-actinium-pharmaceuticals-inc , Annual-global-investment-conference